Analytical Data
-
Gene name
CT83
- Application
-
Alternative Names
Cancer/testis antigen 83
-
Species
Human
-
Source
E. coli
-
Tag
N- His-B2M
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5H943
-
Expression Region
1-113aa
-
Molecular Weight
26.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CT83, also known as cancer/testis antigen 83, is a protein that has garnered significant attention in cancer research due to its restricted expression pattern. It is mainly found in human germ cells in the testis and is aberrantly expressed in various types of cancer, including melanoma, breast cancer, and ovarian cancer. The study of CT83 is vital for several reasons: first, its cancer/testis antigen classification makes it a potential target for immunotherapy, providing opportunities for developing cancer vaccines and personalized treatments. Second, understanding its role in tumorigenesis could unveil new molecular mechanisms underlying cancer development. Research has shown that CT83 may play a role in promoting tumor cell growth and evading immune surveillance, making it a candidate for therapeutic intervention. Moreover, as a biomarker, CT83 can potentially improve cancer diagnosis and prognosis. Thus, ongoing investigations into CT83 encompass its expression profiles, underlying biological functions, and interactions within the tumor microenvironment, contributing to a broader understanding of cancer biology and the development of targeted therapies.
